May 2 (Reuters) - The U.S. Food and Drug Administration

has accepted Novo Nordisk's marketing application for

an oral version of its weight-loss drug Wegovy and will take a

decision by the fourth quarter, the Danish drugmaker said on

Friday.

The company's experimental once-daily version will become

the first oral GLP-1 for chronic weight management, if approved.

Novo Nordisk's oral GLP-1 drug Rybelsus, which also has the

same active ingredient semaglutide, is already approved for

blood sugar control in adults with diabetes.

(Reporting by Sriparna Roy in Bengaluru; Editing by Sriraj

Kalluvila)